| Document |
Document Title |
|
WO/2024/153053A1 |
Provided is compound A in a crystal form or a pharmaceutically acceptable salt thereof. The structure of compound A is as shown in formula (I) below. Studies have shown that a free base crystal form A-I, hydrochloride salt crystal form B...
|
|
WO/2024/153077A1 |
Provided in the present invention are a compound having a skeleton structure as represented by formula (I) or a pharmaceutically acceptable salt, an isotope derivative and a solvate thereof, or a stereoisomer, a geometric isomer and a ta...
|
|
WO/2024/153249A1 |
The present invention provides a compound. Specifically, the present invention provides a compound having a structure represented by formula (I), or an optical isomer, pharmaceutically acceptable salt, prodrug, deuterated derivative, hyd...
|
|
WO/2024/153240A1 |
Disclosed in the present invention are heterocyclic compounds, a preparation method therefor and the use thereof, in particular to the use in Cbl-b inhibition. The compounds have good Cbl-b inhibitory activity, and therefore are expected...
|
|
WO/2024/154148A1 |
The present invention discloses processes for the preparation of 7-(4,7- Diazaspiro[2,5] octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)- pyrido[1,2-a]pyrimidin-4-one i.e. Risdiplam of Formula-1 via novel intermediates namely 7-...
|
|
WO/2024/153568A1 |
The present invention relates to heterocycles that are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said heterocycles.
|
|
WO/2024/153180A1 |
Disclosed in the present invention are a heterocyclic compound, and a pharmaceutical composition thereof and the use thereof. Specifically, disclosed in the present invention are a heterocyclic compound as represented by formula (I), a p...
|
|
WO/2024/155706A1 |
Disclosed herein are tricyclic compounds, together with pharmaceutical compositions and methods for treating a cancer wherein the cancer may be associated with a KRAS mutation.
|
|
WO/2024/153054A1 |
Disclosed in the present invention are a crystal form of an aromatic heterocyclic compound, and a composition comprising same, a preparation method therefor and a use thereof. The crystal form comprises: a crystal form I and a crystal fo...
|
|
WO/2024/153119A1 |
Provided are compounds for the inhibition of KRAS mutans, in particular KRAS G12D, as well as pharmaceutical compositions comprising these compounds and methods of treatment by administration of these compounds or the pharmaceutical comp...
|
|
WO/2024/153208A1 |
Compounds represented by formula (I) or stereoisomers thereof, or pharmaceutically acceptable salts, solvates or prodrugs thereof, each group in the formula being defined in the description, a pharmaceutical composition comprising the co...
|
|
WO/2024/149819A1 |
The present invention relates to compounds of formula (I), wherein R1 to R7, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
|
|
WO/2024/149389A1 |
The present invention relates to a substituted bridge ring inhibitor, a preparation method therefor, and an application thereof. Specifically, the compound of the present invention has the structure represented by formula (A0). The prese...
|
|
WO/2024/150815A1 |
The problem addressed is to provide a novel compound having cereblon E3 ligase binding ability. Provided is a compound represented by formula (I): [in the formula, the symbols are as described in the specification.], formula (II): [in th...
|
|
WO/2024/083258A8 |
Disclosed in the present invention are a KRAS G12D degradation agent, and a preparation method and use therefor. The KRAS G12D degradation agent in the present invention is a compound as shown in formula I or I', and/or a stereoisomer, e...
|
|
WO/2024/149275A1 |
The present invention provides a KRAS inhibitor compound. Specifically disclosed are a heterocyclic compound represented by formula (I-1) or formula (I-2), a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a deuterated ...
|
|
WO/2024/148191A1 |
Provided herein are inhibitors of TNF-α, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNF-α inhibitory compounds for the treatment of diseases or disorders.
|
|
WO/2024/148089A1 |
The present disclosure provides, in part, a compound represented by structural Formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2024/140537A1 |
Provided is the use of a CDK inhibitor compound A in the preparation of an anti-tumor drug, in particular the use in the preparation of a drug for treating CDK4/6 inhibitor-resistant tumors. Also provided is a corresponding treatment met...
|
|
WO/2024/140690A1 |
Disclosed herein are compounds of Formula (I) having protective group of carbonyl used as intermediates for preparing 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((4-(((1r,4r)-4-hyd
roxy-4-methylcyclohexyl)methyl)amino)-3-nitrophenyl)sulfon...
|
|
WO/2024/145483A1 |
Disclosed herein are compounds that inhibit RNA modifying enzymes, such as METTL3, and thus can be used for treating and/or preventing diseases, such as cancers. Also disclosed herein are methods for making and using the disclosed compou...
|
|
WO/2024/138486A1 |
The present disclosure provides certain tetracyclic derivatives that inhibit certain K-Ras proteins and are therefore useful for the treatment of cancers mediated by such proteins. Also provided are pharmaceutical compositions containing...
|
|
WO/2024/140798A1 |
Provided in the present invention is a compound represented by formula I and having Menin-MLL protein-protein interaction inhibitory activity and cell proliferation inhibitory activity. Also provided in the present invention is a use the...
|
|
WO/2024/140851A1 |
The present invention provides a toll-like receptor inhibitor, and preparation therefor and an application thereof. Specifically, the present invention provides a compound as shown in formula I below, a pharmaceutically acceptable salt, ...
|
|
WO/2024/140679A1 |
Described herein are spirocyclic HPK1inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with HPK1.
|
|
WO/2024/141013A1 |
Disclosed is a bicyclic compound used as a FGFR inhibitor, and specifically disclosed is a compound represented by formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprisi...
|
|
WO/2024/130344A1 |
The present invention relates to methods and uses of preventing or treating cancer The method or use may comprise administration of a cancer therapy together with a compound of Formula (I). In the compound of Formula (I) A is a substitut...
|
|
WO/2024/131005A1 |
The present application belongs to the technical field of organic electroluminescence, and relates to an organic compound, an organic electroluminescent device using same, and an electronic apparatus. The organic compound has a structure...
|
|
WO/2024/131942A1 |
The present invention provides a cyclopropane TLR7 and/or TLR8 inhibitor (or antagonist) represented by formula (I) below, which can be used for preventing and/or treating inflammatory diseases, autoimmune diseases, and the like.
|
|
WO/2024/131777A1 |
The present invention relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt and a stereoisomer thereof, and the use thereof in the treatment of tumors, immunological diseases, inflammation and other di...
|
|
WO/2024/133560A1 |
The invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, Z3, Z4, Y1, Y2, Y3, R1, R2, R8, X, L and Hy are as defined herein. The compounds are useful in the treatment of cancer.
|
|
WO/2024/137743A1 |
Provided herein are compounds and compositions thereof for modulating IRAK3. In some embodiments, the compounds and compositions are provided for treatment of cancer.
|
|
WO/2024/131937A1 |
The present invention relates to the field of medicinal chemistry, and relates to a tricyclic compound serving as an eIF4E inhibitor and a use thereof. Specifically, the present invention provides a compound represented by formula (I), o...
|
|
WO/2024/131901A1 |
The present invention relates to an alkynyl-containing substituted heterocyclic amide derivative represented by formula (I), and a preparation method therefor and a use thereof. The present invention also relates to a pharmaceutical comp...
|
|
WO/2024/130408A1 |
The present application relates conjugate compounds of Formula (I): A – L1 – B (I) wherein: A is a moiety that increases fungal cell uptake and/or fungal cell permeability; B is a CK1 inhibiting moiety; and L1 is a linker; or pharmac...
|
|
WO/2024/130342A1 |
The present invention relates to compounds, pharmaceutical compositions of said compounds, and uses of said compounds, especially for inhibition of Transient Receptor Potential channel family, Vanilloid subfamily member 6 (TRPV6). The co...
|
|
WO/2024/132803A1 |
The present invention relates to compounds of the formula (I), a process for its preparation and its use as compound that absorbs light emitted from an irradiation source and optionally emits light different from that of the irradiation ...
|
|
WO/2024/132801A1 |
The present invention relates to compounds of the formula (I) R4 is -SO3-, or a group of formula -SO2NR12R13, a process for its preparation and its use as compound that absorbs light emitted from an irradiation source and optionally emit...
|
|
WO/2024/137587A1 |
The present invention provides compounds of formula (I) for use in the treatment of systemic sclerosis, fibrosis (e.g., pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g., type I), severe achondroplasia with developmental...
|
|
WO/2024/138206A1 |
The present disclosure provides compounds and methods useful in the treatment and suppression of cancer, for example, useful for treating or suppressing cancers characterized by KRAS G12C. Also provided are pharmaceutical compositions co...
|
|
WO/2024/125437A1 |
The present invention belongs to the field of medicinal chemistry, and in particular relates to a compound that acts as a GSPT1 degradation agent, or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof, a pre...
|
|
WO/2024/126773A1 |
A compound with the Formula (I): A-B-C wherein A is of the following formula (AA) and X1 is selected from O, S or NH; X2 is either N or C-H; X3 is either N or C-RA3; wherein if X1 is NH and X2 is C-H then X3 is C-RA3; B is of formula (B-...
|
|
WO/2024/125600A1 |
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, tautomers, or stereoisomers and solvates thereof, said compounds being used in the treatment of cancers and inflammations in mammal...
|
|
WO/2024/129395A1 |
The present invention is directed to the compounds of Formula (A) - (G) and (I) - (XXII) - inhibitors of BTK. The inhibitors described herein can be useful in the treatment of diseases or disorders associated with BTK, such as Lymphoma. ...
|
|
WO/2024/126987A1 |
The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity, wherein Formula (I) is as defined herein. The present invention also relates...
|
|
WO/2024/130062A1 |
The invention provides substituted tetrahydropyrrolo-pyridinone compounds, pharmaceutical compositions, and their use in treating muscarinic acetylcholine receptor mediated disorders.
|
|
WO/2024/130095A1 |
Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., for degrading certain proteins such as p300/CBP proteins).
|
|
WO/2024/125603A1 |
The present invention pertains to the technical field of pharmaceuticals, and relates to an SHP2 inhibitor and use thereof. In particular, the present invention relates to a compound represented by formula (I), an isomer thereof, a deute...
|
|
WO/2024/129715A1 |
Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with the activation of p53.
|
|
WO/2024/125662A1 |
The present invention provides a preparation and application of a novel biaryl ring compound as an immunomodulator, and specifically, the present invention provides: a compound as shown in the following formula (I), or an optical isomer,...
|
